FRESENIUS SE &/S (OTCMKTS: FSNUY) and LeMaitre Vascular (NASDAQ:LMAT) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, dividends, analyst recommendations, earnings, institutional ownership, risk and valuation.
Risk & Volatility
FRESENIUS SE &/S has a beta of 1.01, indicating that its stock price is 1% more volatile than the S&P 500. Comparatively, LeMaitre Vascular has a beta of 0.59, indicating that its stock price is 41% less volatile than the S&P 500.
FRESENIUS SE &/S pays an annual dividend of $0.15 per share and has a dividend yield of 0.8%. LeMaitre Vascular pays an annual dividend of $0.28 per share and has a dividend yield of 0.8%. LeMaitre Vascular pays out 32.6% of its earnings in the form of a dividend. LeMaitre Vascular has raised its dividend for 2 consecutive years.
This table compares FRESENIUS SE &/S and LeMaitre Vascular’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|FRESENIUS SE &/S||5.37%||8.76%||3.52%|
Institutional & Insider Ownership
0.1% of FRESENIUS SE &/S shares are held by institutional investors. Comparatively, 73.5% of LeMaitre Vascular shares are held by institutional investors. 20.3% of LeMaitre Vascular shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
This is a summary of current ratings and price targets for FRESENIUS SE &/S and LeMaitre Vascular, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|FRESENIUS SE &/S||1||0||0||0||1.00|
LeMaitre Vascular has a consensus price target of $37.67, suggesting a potential upside of 2.97%. Given LeMaitre Vascular’s stronger consensus rating and higher probable upside, analysts plainly believe LeMaitre Vascular is more favorable than FRESENIUS SE &/S.
Valuation and Earnings
This table compares FRESENIUS SE &/S and LeMaitre Vascular’s revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|FRESENIUS SE &/S||$38.28 billion||1.11||$2.05 billion||N/A||N/A|
|LeMaitre Vascular||$100.87 million||7.00||$17.17 million||$0.86||42.53|
FRESENIUS SE &/S has higher revenue and earnings than LeMaitre Vascular.
LeMaitre Vascular beats FRESENIUS SE &/S on 11 of the 16 factors compared between the two stocks.
FRESENIUS SE &/S Company Profile
Fresenius SE & Co. KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care worldwide. The company operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure. This segment offers dialyzers, hemodialysis machines, and related disposable products, as well as dialysis- related services. The Fresenius Kabi segment specializes in the therapy and care of chronically and critically ill patients. This segment offers IV drugs, including intravenously administered generic anesthetics, analgesics, anti-infectives, and drugs for the treatment of oncological and other critical diseases; parenteral and enteral nutrition products; infusion solutions and blood volume substitutes for infusion therapy; infusion and nutrition pumps, as well as consumables; and products used in the collection and processing of blood components, as well as in transfusion medicine. The Fresenius Helios segment operates 111 hospitals with approximately 35,000 beds, such as 88 acute care hospitals and 23 post-acute care clinics; 4 post-acute care centers; 17 prevention centers; and 12 nursing homes. The Fresenius Vamed segment manages projects and provides services for hospitals and other health care facilities. This segment offers project development, planning, and turnkey construction services, as well as maintenance, technical management, and operational management services. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is headquartered in Bad Homburg vor der Höhe, Germany.
LeMaitre Vascular Company Profile
LeMaitre Vascular, Inc. designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. The company offers angioscope, a fiber optic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to temporarily perfuse the blood and other fluids into the vasculature. It also provides carotid shunts that temporarily shunt the blood to the brain during the removal of plaque from the carotid artery in a carotid endarterectomy surgery; powered phlebectomy devices to remove varicose veins; and radiopaque tape, a medical-grade tape applied to the skin that enables interventionists to cross-refer between the inside and the outside of a patient's body, and allows them to locate tributaries or lesions beneath the skin. In addition, the company offers remote endarterectomy devices to remove plaque from arteries in the leg; valvulotomes that cuts valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and vascular grafts to bypass or replace diseased arteries. Further, it provides vascular patches, which are used for closure of vessels after surgical intervention, as well as endarterectomy and other vascular reconstruction; vessel closure systems to attach vessels to one another with titanium clips instead of sutures; and Reddick cholangiogram catheters to inject dye into the cystic duct during laparoscopic cholecystectomy, as well as laparoscopic accessory for use in laparoscopic gall bladder removal. LeMaitre Vascular, Inc. markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was founded in 1983 and is headquartered in Burlington, Massachusetts.
Receive News & Ratings for FRESENIUS SE &/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FRESENIUS SE &/S and related companies with MarketBeat.com's FREE daily email newsletter.